Discontinuing osteoporosis pharmacotherapy in postmenopausal women – can they risk taking a break? Clinical Brief Series - Certificate of Completion

Duration

1 hr

Profession

Physician

# of Credits

2.0

Accreditation

Certificate of Completion

Expiry Date

2021-06-07

This is a 4-part Clinical Brief series that has been accredited with RACGP. Participants must read all 4 issues and then complete the questions on Issue 4 to claim CPD points.Please ensure that you have read all four parts of this Clinical Brief series, then complete the following 5 questions in order to claim your CPD points.

This interactive online learning activity is valued at 1 Hour(s) of continuing education.

Damian Flanagan
MBBS, MWell, DipRACOG
South Coast Medical
Blairgowrie, Victoria, Australia

On completion of this program, participants will be better able to:

  1. Recall the different modes of action, onset of action and duration of action of osteoporosis pharmacotherapies
  2. Counsel patients on the safety and efficacy of long-term osteoporosis pharmacotherapy
  3. Evaluate the benefits and risks of long-term osteoporosis pharmacotherapy, including the risk of osteonecrosis of the jaw (ONJ) and atypical fracture of the femur (AFF)
  4. Implement strategies for discontinuation of osteoporosis pharmacotherapies in order to minimise the risk of rebound fracture


Related Courses